Moderna Adds Chief Operating Officer Role as Company Expands into Oncology
Key Highlights
- ➤Juan Andres returns as Moderna's (MRNA) Chief Operating Officer October 5, 2026
- ➤Moderna (MRNA) prepares potential intismeran autogene launch and scale-up after positive Phase 3 results
- ➤Moderna (MRNA) infectious disease franchise reaches five approved vaccines
- ➤Jerh Collins, Ph.D., retires as Chief Technical Operations and Quality Officer
Expert Statements
Stéphane Bancel, Chief Executive Officer of Moderna
“I am very pleased to welcome Juan back to Moderna as our Chief Operating Officer. As we enter the next chapter of Moderna, Juan's experience leading complex global operations will be invaluable. He knows Moderna deeply and was an extraordinary partner to me as we built and scaled the Company. I look forward to working with him again as we execute on our strategy.”
Juan Andres, Chief Operating Officer of Moderna
“I am excited to return to Moderna at such an important moment for the Company. Moderna has always been a special place to me, and the opportunity ahead is tremendous. I look forward to working with Stéphane and colleagues across the Company to execute on our priorities and deliver more mRNA medicines to patients around the world.”
Stéphane Bancel, Chief Executive Officer of Moderna
“I am also deeply grateful to Jerh for his leadership, partnership and commitment to Moderna over the past four years. He has made significant contributions to our Company and built a very strong team that will carry forward the important work of manufacturing and technical operations. I wish Jerh and his family all the best in his retirement.”
Jerh Collins, Chief Technical Operations and Quality Officer of Moderna
“It has been a privilege to be part of Moderna and to lead our Technical Operations and Quality organization. I am incredibly proud of what our teams have accomplished together for patients, and grateful to the many colleagues I have had the opportunity to work alongside. As I look ahead to retirement, I have great confidence in the team and in Moderna's future.”
CAMBRIDGE, MA / ACCESS Newswire / September 30, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced the addition of a Chief Operating Officer role to support the increasing scale and diversification of the Company.
The new role comes as Moderna prepares for the potential launch and scale-up of intismeran autogene following positive Phase 3 results and continues to advance a broader oncology portfolio. The Company has also expanded the infectious disease franchise, which now includes five approved vaccines following the recent U.S. FDA approval of Moderna's seasonal flu vaccine and the European Commission marketing authorization of the Company's seasonal flu plus COVID combination vaccine.
Get started
Create a free account to read the full story.